Table 2.
Baseline Characteristics of Patients with High and Low Baseline HBV DNA Level
| Characteristics | DNA Level ≤2000 IU/mL | DNA Level >2000 IU/mL | P value |
|---|---|---|---|
| Sample size | 137 | 116 | |
| Age (years) | 50.69±11.86 | 50.72±11.96 | 0.988 |
| Gender | 0.998 | ||
| Male | 117 (85.4) | 100 (86.2) | |
| Female | 20 (14.6) | 16 (13.8) | |
| HBeAg | 0.141 | ||
| Positive | 26 (19.0) | 32 (27.6) | |
| Negative | 111 (81.0) | 84 (72.4) | |
| BCLC stage | 0.611 | ||
| B | 34(24.8) | 33 (28.4) | |
| C | 103 (75.2) | 83 (71.6) | |
| AFP, ng/mL | 0.262 | ||
| ≤200 | 59 (43.1) | 41 (35.3) | |
| >200 | 78 (56.9) | 75 (64.7) | |
| a ALBI grade | 0.034 | ||
| I | 68 (49.6) | 40 (34.5) | |
| II | 68 (49.6) | 73 (62.9) | |
| III | 1 (0.7) | 3 (2.6) | |
| Cirrhosis | 0.454 | ||
| Yes | 47 (34.3) | 46 (39.7) | |
| No | 90 (65.7) | 70 (60.3) | |
| Treatment modality | 0.019 | ||
| b AP alone | 23 (16.8) | 8 (6.9) | |
| AP withc TD | 42 (30.7) | 27 (23.3) | |
| AP withd LT | 33 (24.1) | 32 (27.6) | |
| AP with TD and LT | 39 (28.5) | 49 (42.2) | |
| Antiviral therapy | 0.057 | ||
| Yes | 104 (75.9) | 100 (86.2) | |
| No | 33 (24.1) | 16 (13.8) |
Abbreviations: aALBI, albumin-bilirubin grade; bAP, anti-PD-1 immunotherapy; cTD, targeted drugs; dLT, local treatments.